Asset
ABT-510
Abbott Laboratories Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00061646 | phase2 | terminated | 2003-03-01 | — | Abbott | Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC) |
| NCT00073125 | phase2 | completed | 2003-05-01 | — | Abbott | Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma |
FDA applications (0)
This company has no applications containing this asset.